[1]
|
Neuro-Ophthalmology Group of Ophthalmology Branch of Chinese Medical Association; Evidence-Based Medicine Center of Lanzhou University/World Health Organization Collaborating Centre for Guideline Implementation and Knowledge Translation (2021) Evidence-Based Guidelines for Diagnosis and Treatment of Demyelinating Optic Neuritis in China (2021). Chinese Journal of Ophthalmology, 57, 171-186.
|
[2]
|
Schluesener, H., Sobel, R., Linington, C., et al. (1987) A Monoclonal Antibody against a Myelin Oligodendrocyte Glycoprotein Induces Relapses and Demyelination in Central Nervous System Autoimmune Disease. Journal of Immunology (Baltimore, Md: 1950), 139, 4016-4021. https://doi.org/10.4049/jimmunol.139.12.4016
|
[3]
|
Kezuka, T. and Ishikawa, H. (2018) Diagnosis and Treatment of Anti-Myelin Oligodendrocyte Glycoprotein Antibody Positive Optic Neuritis. Japanese Journal of Ophthalmology, 62, 101-108. https://doi.org/10.1007/s10384-018-0561-1
|
[4]
|
Reindl, M., Di Pauli, F., Rostásy, K., et al. (2013) The Spectrum of MOG Autoantibody-Associated Demyelinating Diseases. Nature Reviews Neurology, 9, 455-461. https://doi.org/10.1038/nrneurol.2013.118
|
[5]
|
Stiebel-Kalish, H., Lotan, I., Brody, J., et al. (2017) Retinal Nerve Fiber Layer May Be Better Preserved in MOG-IgG versus AQP4-IgG Optic Neuritis: A Cohort Study. PLOS ONE, 12, e0170847.
https://doi.org/10.1371/journal.pone.0170847
|
[6]
|
Yao, Y., Li, X., Xu, Y., et al. (2022) The Difference of the Ret-inal Structural and Microvascular Characteristics in Patients with MOGAD-ON and AQP4-ON. BMC Neurology, 22, 323. https://doi.org/10.1186/s12883-022-02848-2
|
[7]
|
De Mol, C., Wong, Y., Van Pelt, E., et al. (2020) The Clin-ical Spectrum and Incidence of Anti-MOG-Associated Acquired Demyelinating Syndromes in Children and Adults. Mul-tiple Sclerosis (Houndmills, Basingstoke, England), 26, 806-814. https://doi.org/10.1177/1352458519845112
|
[8]
|
Boesen, M., Jensen, P., Born, A., et al. (2019) Incidence of Pedi-atric Neuromyelitis Optica Spectrum Disorder and Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease in Denmark 2008-2018: A Nationwide, Population-Based Cohort Study. Multiple Sclerosis and Related Disorders, 33, 162-167.
https://doi.org/10.1016/j.msard.2019.06.002
|
[9]
|
Jarius, S., Ruprecht, K., Kleiter, I., et al. (2016) MOG-IgG in NMO and Related Disorders: A Multicenter Study of 50 Patients. Part 1: Frequency, Syndrome Specificity, Influence of Disease Activity, Long-Term Course, Association with AQP4-IgG, and Origin. Journal of Neuroinflammation, 13, 279. https://doi.org/10.1186/s12974-016-0717-1
|
[10]
|
Chen, J., Flanagan, E., Jitprapaikulsan, J., et al. (2018) Myelin Oligodendrocyte Glycoprotein Antibody-Positive Optic Neuritis: Clinical Characteristics, Radiologic Clues, and Outcome. American Journal of Ophthalmology, 195, 8-15.
https://doi.org/10.1016/j.ajo.2018.07.020
|
[11]
|
Ramanathan, S., Mohammad, S., Tantsis, E., et al. (2018) Clinical Course, Therapeutic Responses and Outcomes in Relapsing MOG Antibody-Associated Demyelination. Journal of Neurology, Neurosurgery, and Psychiatry, 89, 127-137.
https://doi.org/10.1136/jnnp-2017-316880
|
[12]
|
Chen, J. and Bhatti, M. (2020) Clinical Phenotype, Radiological Features, and Treatment of Myelin Oligodendrocyte Glycoprotein-Immunoglobulin G (MOG-IgG) Optic Neuritis. Cur-rent Opinion in Neurology, 33, 47-54.
https://doi.org/10.1097/WCO.0000000000000766
|
[13]
|
Chen, Q., Zhao, G., Huang, Y., et al. (2018) Clinical Characteristics of Pediatric Optic Neuritis with Myelin Oligodendrocyte Glycoprotein Seropositive: A Cohort Study. Pe-diatric Neurology, 83, 42-49.
https://doi.org/10.1016/j.pediatrneurol.2018.03.003
|
[14]
|
Saitakis, G. and Chwalisz, B. (2022) Treatment and Re-lapse Prevention of Typical and Atypical Optic Neuritis. International Journal of Molecular Sciences, 23, Article No. 9769. https://doi.org/10.3390/ijms23179769
|
[15]
|
孟超, 赖春涛, 陶建华, 等. 髓鞘少突胶质细胞糖蛋白抗体阳性视神经炎临床特征及预后分析[J]. 中华医学杂志, 2021, 101(19): 1415-1420.
|
[16]
|
Pineles, S., Henderson, R., Repka, M., et al. (2022) The Pediatric Optic Neuritis Prospective Outcomes Study: Two-Year Results. Ophthalmology, 129, 856-864.
|
[17]
|
Ramanathan, S., Reddel, S., Henderson, A., et al. (2014) Antibodies to Myelin Oligodendrocyte Glycoprotein in Bilateral and Recurrent Optic Neuritis. Neurology(R) Neuroimmunology & Neuroinflammation, 1, e40.
https://doi.org/10.1212/NXI.0000000000000040
|
[18]
|
Song, H., Zhou, H., Yang, M., et al. (2019) Clinical Char-acteristics and Prognosis of Myelin Oligodendrocyte Glycoprotein Antibody-Seropositive Paediatric Optic Neuritis in China. The British Journal of Ophthalmology, 103, 831-836.
https://doi.org/10.1136/bjophthalmol-2018-312399
|
[19]
|
Hacohen, Y., Wong, Y., Lechner, C., et al. (2018) Disease Course and Treatment Responses in Children with Relapsing Myelin Oligodendrocyte Glycoprotein Anti-body-Associated Disease. JAMA Neurology, 75, 478-487.
https://doi.org/10.1001/jamaneurol.2017.4601
|
[20]
|
孔秀云, 王佳伟, 景筠. 106例抗髓鞘少突胶质细胞糖蛋白免疫球蛋白G抗体阳性与抗水通道蛋白4免疫球蛋白G抗体阳性视神经炎患者临床特征比较及预后因素分析[J]. 中华神经科杂志, 2021, 54(9): 889-897.
|
[21]
|
Chen, J., Flanagan, E., Bhatti, M., et al. (2022) Details and Out-comes of a Large Cohort of MOG-IgG Associated Optic Neuritis. Multiple Sclerosis and Related Disorders, 68, Article ID: 104237.
https://doi.org/10.1016/j.msard.2022.104237
|
[22]
|
Ramanathan, S., Prelog, K., Barnes, E., et al. (2016) Radiological Differentiation of Optic Neuritis with Myelin Oligodendrocyte Glycoprotein Antibodies, Aquaporin-4 Antibodies, and Multiple Sclerosis. Multiple Sclerosis (Houndmills, Basingstoke, England), 22, 470-482. https://doi.org/10.1177/1352458515593406
|
[23]
|
Lock, J., Newman, N., Biousse, V., et al. (2019) Update on Pedi-atric Optic Neuritis. Current Opinion in Ophthalmology, 30, 418-425. https://doi.org/10.1097/ICU.0000000000000607
|
[24]
|
Wendel, E., Baumann, M., Barisic, N., et al. (2020) High Association of MOG-IgG Antibodies in Children with Bilateral Optic Neuritis. European Journal of Paediatric Neurol-ogy: EJPN: Official Journal of the European Paediatric Neurology Society, 27, 86-93. https://doi.org/10.1016/j.ejpn.2020.04.002
|
[25]
|
Winter, A. and Chwalisz, B. (2020) MRI Characteristics of NMO, MOG and MS Related Optic Neuritis. Seminars in Ophthalmology, 35, 333-342. https://doi.org/10.1080/08820538.2020.1866027
|
[26]
|
Banwell, B., Bennett, J., Marignier, R., et al. (2023) Diagno-sis of Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease: International MOGAD Panel Proposed Cri-teria. The Lancet Neurology, 22, 268-282.
https://doi.org/10.1016/S1474-4422(22)00431-8
|
[27]
|
Filippatou, A., Mukharesh, L., Saidha, S., et al. (2020) AQP4-IgG and MOG-IgG Related Optic Neuritis-Prevalence, Optical Coherence Tomography Findings, and Visual Outcomes: A Systematic Review and Meta-Analysis. Frontiers in Neurology, 11, Article ID: 540156. https://doi.org/10.3389/fneur.2020.540156
|
[28]
|
Oertel, F., Sotirchos, E., Zimmermann, H., et al. (2022) Longitu-dinal Retinal Changes in MOGAD. Annals of Neurology, 92, 476-485. https://doi.org/10.1002/ana.26440
|
[29]
|
Lin, T., Chien, C., Lu, A., et al. (2021) Retinal Optical Coherence Tomography and Magnetic Resonance Imaging in Neuro-myelitis Optica Spectrum Disorders and MOG-Antibody Associated Disorders: An Updated Review. Expert Review of Neurotherapeutics, 21, 1101-1123. https://doi.org/10.1080/14737175.2021.1982697
|
[30]
|
Akaishi, T., Himori, N., Takeshita, T., et al. (2022) Follow-Up of Retinal Thickness and Optic MRI after Optic Neuritis in Anti-MOG Anti-body-Associated Disease and Anti-AQP4 Antibody-Positive NMOSD. Journal of the Neurological Sciences, 437, Arti-cle ID: 120269. https://doi.org/10.1016/j.jns.2022.120269
|
[31]
|
Mase, T., Ishibazawa, A., Nagaoka, T., et al. (2016) Radial Peripapillary Capillary Network Visualized Using Wide- Field Montage Optical Coherence Tomography Angi-ography. Investigative Ophthalmology & Visual Science, 57, OCT504- 10. https://doi.org/10.1167/iovs.15-18877
|
[32]
|
Yu, J., Huang, Y., Quan, C., et al. (2021) Alterations in the Retinal Vascular Network and Structure in MOG Antibody-Associated Disease: An Optical Coherence Tomography Angi-ography Study. Journal of Neuro-Ophthalmology: The Official Journal of the North American Neuro-Ophthalmology Society, 41, e424-e432.
https://doi.org/10.1097/WNO.0000000000001116
|
[33]
|
Armangue, T., Olivé-Cirera, G., Martínez-Hernandez, E., et al. (2020) Associations of Paediatric Demyelinating and Encephalitic Syndromes with Myelin Oligodendrocyte Glyco-protein Antibodies: A Multicentre Observational Study. The Lancet Neurology, 19, 234-246. https://doi.org/10.1016/S1474-4422(19)30488-0
|
[34]
|
Waters, P., Fadda, G., Woodhall, M., et al. (2020) Serial An-ti-Myelin Oligodendrocyte Glycoprotein Antibody Analyses and Outcomes in Children with Demyelinating Syndromes. JAMA Neurology, 77, 82-93.
https://doi.org/10.1001/jamaneurol.2019.2940
|
[35]
|
Bruijstens, A., Lechner, C., Flet-Berliac, L., et al. (2020) E.U. Paediatric MOG Consortium Consensus: Part 1—Classification of Clinical Phenotypes of Paediatric Myelin Oligoden-drocyte Glycoprotein Antibody-Associated Disorders. European Journal of Paediatric Neurology: EJPN: Official Jour-nal of the European Paediatric Neurology Society, 29, 2-13. https://doi.org/10.1016/j.ejpn.2020.10.006
|
[36]
|
Marignier, R., Hacohen, Y., Cobo-Calvo, A., et al. (2021) Mye-lin-Oligodendrocyte Glycoprotein Antibody-Associated Disease. The Lancet Neurology, 20, 762-772. https://doi.org/10.1016/S1474-4422(21)00218-0
|
[37]
|
Stiebel-Kalish, H., Hellmann, M., Mimouni, M., et al. (2019) Does Time Equal Vision in the Acute Treatment of a Cohort of AQP4 and MOG Optic Neuritis? Neurology(R) Neuro-immunology & Neuroinflammation, 6, e572.
https://doi.org/10.1212/NXI.0000000000000572
|
[38]
|
Korinthenberg, R., Schessl, J., Kirschner, J., et al. (2005) Intravenously Administered Immunoglobulin in the Treatment of Childhood Guillain-Barré Syndrome: A Randomized Trial. Pediatrics, 116, 8-14.
https://doi.org/10.1542/peds.2004-1324
|
[39]
|
Wynford-Thomas, R., Jacob, A. and Tomassini, V. (2019) Neurolog-ical Update: MOG Antibody Disease. Journal of Neurology, 266, 1280-1286. https://doi.org/10.1007/s00415-018-9122-2
|
[40]
|
Chen, J., Flanagan, E., Bhatti, M., et al. (2020) Steroid-Sparing Maintenance Immunotherapy for MOG-IgG Associated Disorder. Neurology, 95, e111-e120. https://doi.org/10.1212/WNL.0000000000009758
|
[41]
|
Li, S., Ren, H., Xu, Y., et al. (2020) Long-Term Efficacy of Mycophenolate Mofetil in Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disorders: A Prospective Study. Neurology(R) Neuroimmunology & Neuroinflammation, 7, e705. https://doi.org/10.1212/NXI.0000000000000705
|
[42]
|
Durozard, P., Rico, A., Boutiere, C., et al. (2020) Compari-son of the Response to Rituximab between Myelin Oligodendrocyte Glycoprotein and Aquaporin-4 Antibody Diseases. Annals of Neurology, 87, 256-266.
https://doi.org/10.1002/ana.25648
|
[43]
|
Whittam, D., Cobo-Calvo, A., Lopez-Chiriboga, A., et al. (2020) Treatment of MOG-IgG-Associated Disorder with Rituximab: An International Study of 121 Patients. Multiple Sclerosis and Re-lated Disorders, 44, Article ID: 102251.
https://doi.org/10.1016/j.msard.2020.102251
|
[44]
|
Chen, J., Huda, S., Hacohen, Y., et al. (2022) Association of Maintenance Intravenous Immunoglobulin with Prevention of Relapse in Adult Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease. JAMA Neurology, 79, 518-525. https://doi.org/10.1001/jamaneurol.2022.0489
|
[45]
|
Jurynczyk, M., Messina, S., Woodhall, M., et al. (2017) Clini-cal Presentation and Prognosis in MOG-Antibody Disease: A UK Study. Brain: A Journal of Neurology, 140, 3128-3138. https://doi.org/10.1093/brain/awx276
|
[46]
|
Vosoughi, A. and Micieli, J. (2020) Resolution of Myelin Oligodendrocyte Glycoprotein (MOG)-IgG Optic Neuritis without Treatment. Multiple Sclerosis and Related Disorders, 46, Article ID: 102456.
https://doi.org/10.1016/j.msard.2020.102456
|